Nerandomilast (PDE4B inhibitor) joined nintedanib and pirfenidone as FDA-approved options, with each demonstrating reduced FVC decline rates in IPF. Clinical benefit is clearest in progressive ...
Patients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of lung function with favorable tolerability Findings further substantiate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results